Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fludrocortisone is a synthetic corticosteroid with potent mineralocorticoid properties and moderate glucocorticoid activity. It is primarily used as partial replacement therapy for primary or secondary adrenocortical insufficiency (such as Addison's disease) and for the treatment of salt-losing adrenogenital syndrome (congenital adrenal hyperplasia). Fludrocortisone acts mainly by mimicking the effects of aldosterone, increasing sodium reabsorption and potassium excretion in the kidneys, thereby helping to regulate plasma electrolyte composition and blood pressure. It is administered orally, most commonly in its acetate form. Fludrocortisone may also be used off-label for conditions such as postural orthostatic tachycardia syndrome (POTS), cerebral salt-wasting syndrome, and as part of diagnostic testing for Conn’s syndrome[1][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fludrocortisone.